Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903855 | 0.82 | GPR27 (0.46) | SCN10ASCN9ASCN2ASCN3APIK3CD | |
| SCHEMBL17512523 | 0.81 | CFTR (0.38) | SCN10ASCN9ASCN2ASCN3APIK3CD | |
| SCHEMBL17512626 | 0.79 | NQO2 (0.44) | KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL17512549 | 0.79 | CFTR (0.40) | SCN10ASCN9ASCN2ASCN3APIK3CD | |
| SCHEMBL26795970 | 0.77 | KMT2A (0.43) | PIK3CDPIK3CAPIK3CGPIK3CBKDM4E | |
| SCHEMBL8771575 | 0.76 | ALDH1A1 (0.40) | — | |
| SCHEMBL19172612 | 0.76 | CFTR (0.43) | SCN10ASCN9ASCN2ASCN3APIK3CD | |
| SCHEMBL29883149 | 0.76 | ALDH1A1 (0.40) | — | |
| SCHEMBL14903879 | 0.76 | BACE1 (0.44) | — | |
| SCHEMBL16572965 | 0.72 | MAPT (0.43) | SCN10ASCN9ASCN2ASCN3APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957683-B2 | Bicyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230051483-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230051483-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2022266193-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-11197867-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210377495-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2021-12-02 | — | — | US | disclosed |
| CN-108473499-B | Novel pyrazolopyrimidine derivatives | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10980815-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200330477-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | NOVARTIS PHARMA AG (CH) | 2020-09-17 | — | — | US | disclosed |
| US-10463675-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3374361-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| EP-3183247-B9 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3183247-B1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170239264-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3183247-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | Pfizer Inc (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9663526-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2017081641-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| US-20160052930-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2016027195-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER INC. (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051483-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | SCN10A 474/4885SCN9A 490/4885SCN2A 786/4885 |
| US-10463675-B2 | Aminopyrimidinyl compounds | JAK2, JAK1, JAK3 | SCN10A 1345/4885SCN9A 1081/4885SCN2A 1121/4885 |
| US-11197867-B2 | Aminopyrimidinyl compounds | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 | SCN10A 346/4885SCN9A 973/4885SCN2A 952/4885 |
| US-10980815-B2 | Aminopyrimidinyl compounds | JAK2, JAK1, JAK3 | SCN10A 1345/4885SCN9A 1081/4885SCN2A 1121/4885 |
| US-11957683-B2 | Bicyclic compounds | SLC10A1, PKD1, CYP11B2 | SCN10A 474/4885SCN9A 490/4885SCN2A 786/4885 |
| US-20200330477-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 | SCN10A 346/4885SCN9A 973/4885SCN2A 952/4885 |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | MMEL1, PPME1, CTSC | SCN10A 4210/4885SCN9A 4522/4885SCN2A 4197/4885 |
| US-20170239264-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | SCN10A 302/4885SCN9A 936/4885SCN2A 825/4885 |
| US-20160052930-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | SCN10A 302/4885SCN9A 936/4885SCN2A 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.